Relay Therapeutics' early clinical data for cancer drug RLY-2608 sparked investor concerns due to lack of robust evidence of efficacy, leading to a 40% stock decline. Despite investor skepticism, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback